Trump Administration Pushes Congress on Drug Pricing Policy | STAT News

Fine morning. The STAT Breakthrough East Summit kicks off this Thursday in Modern York City, bringing together leaders in health, medicine, and life sciences. Speakers include Chris Klomp, a top official at the Centers for Medicare & Medicaid Services (CMS), and former FDA Commissioner Robert Califf. A full agenda is available online, and a 40% discount on virtual passes is still available.

White House Intensifies Push for Drug Pricing Policy

The Biden administration is increasing pressure on Congress to pass legislation that would formalize a “most-favored nation” (MFN) drug pricing policy, according to reports. This policy, initially proposed during the Trump administration, aims to lower drug costs for Medicare by tying prices to those paid in other developed countries. The current effort comes as the administration faces ongoing scrutiny over prescription drug affordability and access.

The MFN rule, as originally conceived, would have required drug manufacturers to charge Medicare the same prices for certain drugs that they charge in a basket of other countries – specifically, those in the Organisation for Economic Co-operation and Development (OECD) with comparable income levels. The Centers for Medicare & Medicaid Services (CMS) finalized the rule in 2022, but it faced legal challenges and was ultimately paused. The Biden administration has signaled its intent to revive a similar policy, but requires congressional action to ensure its long-term viability.

What is “Most Favored Nation” Pricing?

The concept of “most favored nation” pricing isn’t new to international trade. It generally refers to a trade agreement where a country guarantees that any trade advantage it grants to one nation will automatically be extended to all other nations. Applying this principle to pharmaceuticals is complex. Proponents argue it would leverage the negotiating power of the U.S. Government to secure lower drug prices, aligning them more closely with those in countries where governments directly negotiate with manufacturers. Critics, however, contend that it could disrupt the pharmaceutical market, potentially leading to reduced innovation and limited access to certain medications.

The core argument centers on the significant price discrepancies between the U.S. And other developed nations. For example, a 2021 report by the Kaiser Family Foundation (KFF) found that prescription drug prices in the U.S. Are, on average, 2.56 times higher than in other OECD countries. This difference is often attributed to the U.S.’s unique system of allowing market forces to largely determine drug prices, rather than government regulation.

The Current Congressional Landscape

The path forward for MFN legislation in Congress is uncertain. Even as there is bipartisan support for lowering drug costs, lawmakers disagree on the best approach. Some favor allowing Medicare to negotiate drug prices directly, a provision included in the Inflation Reduction Act of 2022, while others support the MFN model. The pharmaceutical industry has actively lobbied against both approaches, arguing that they would stifle innovation and reduce investment in research and development.

The Trump administration’s initial attempt to implement the MFN rule faced legal challenges from the pharmaceutical industry, which argued that the rule exceeded the authority of the Department of Health and Human Services (HHS). A federal court ultimately blocked the rule from taking effect. Any new legislation would need to address these legal concerns to withstand potential challenges.

Chris Klomp’s Role and CMS Oversight

The involvement of Chris Klomp, Director of the Center for Medicare and a Deputy Administrator of CMS, in the STAT Breakthrough East Summit is noteworthy. Klomp, who also serves as chief counselor of the U.S. Department of Health and Human Services (HHS) since February 2026, is a key figure in the administration’s efforts to reform drug pricing. His background includes experience in both consulting and healthcare technology, and he has been involved in initiatives aimed at improving healthcare data sharing and interoperability. His presence at the summit suggests CMS will continue to play a central role in shaping the debate over drug pricing policy.

Looking Ahead: What to Expect in Drug Pricing Reform

The debate over drug pricing is likely to continue throughout 2026 and beyond. Several key factors will shape the outcome, including the results of ongoing legal challenges to the Inflation Reduction Act, the evolving political landscape in Congress, and the continued pressure from the administration to lower drug costs. Further legislative action, potentially building on the MFN concept or exploring alternative approaches, remains a possibility. The focus will likely be on balancing the goals of affordability, access, and innovation in the pharmaceutical market.

The STAT Breakthrough East Summit provides a crucial forum for discussing these complex issues and exploring potential solutions. The participation of key policymakers like Chris Klomp and industry leaders like Robert Califf underscores the importance of this conversation.